SCHEMBL25680418

SCHEMBL25680418

CC(=O)c1ccccc1NC(=O)c1ccc(OCc2c(C)noc2C)cc1

nearest known ligand 0.77

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.77
RAB9A P51151 2/20 0.68
L3MBTL1 Q9Y468 2/20 0.67
RECQL P46063 1/20 0.67
SMN1; SMN2 Q16637 2/20 0.64
MAPT P10636 2/20 0.64
HPGD P15428 1/20 0.64
NPC1 O15118 1/20 0.62
POLB P06746 1/20 0.61
MDM2 Q00987 1/20 0.61
GAA P10253 1/20 0.61
AKR1C3 P42330 5/20 0.60
ALDH1A1 P00352 3/20 0.57
KDM4E B2RXH2 1/20 0.57
TSHR P16473 1/20 0.57
NPSR1 Q6W5P4 1/20 0.57
HSD17B10 Q99714 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25680301 0.89 SMN1; SMN2 (0.79) LMNARAB9AL3MBTL1RECQLSMN1; SMN2
SCHEMBL25680259 0.86 LMNA (0.71) LMNARAB9AL3MBTL1RECQLSMN1; SMN2
SCHEMBL20510895 0.85 LMNA (0.70) LMNARAB9AL3MBTL1RECQLSMN1; SMN2
SCHEMBL20511375 0.85 LMNA (0.70) LMNARAB9AL3MBTL1RECQLSMN1; SMN2
SCHEMBL25680284 0.85 LMNA (0.70) LMNARAB9AL3MBTL1RECQLSMN1; SMN2
SCHEMBL20511144 0.85 LMNA (0.67) LMNARAB9AL3MBTL1RECQLSMN1; SMN2
SCHEMBL25680291 0.85 LMNA (0.69) LMNARAB9AL3MBTL1RECQLSMN1; SMN2
SCHEMBL20511142 0.84 LMNA (0.66) LMNARAB9AL3MBTL1RECQLSMN1; SMN2
SCHEMBL20511302 0.83 LMNA (0.67) LMNARAB9AL3MBTL1RECQLSMN1; SMN2
SCHEMBL20511326 0.83 LMNA (0.67) LMNARAB9AL3MBTL1RECQLSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230142508-A1 COMPOUNDS AND METHODS FOR REGULATING INSULIN SECRETION THE BROAD INSTITUTE, INC. (US) 2023-05-11 US disclosed
US-20230142508-A1 COMPOUNDS AND METHODS FOR REGULATING INSULIN SECRETION THE BROAD INSTITUTE, INC. (US) 2023-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230142508-A1 COMPOUNDS AND METHODS FOR REGULATING INSULIN SECRETION IAPP, GPR119, PNLIP LMNA 4022/4885RAB9A 2004/4885L3MBTL1 4167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.